BioGaia, a Swedish healthcare company, is expanding its product portfolio by developing new bacterial strains for probiotic products. To support this development, BioGaia and its subsidiary MetaboGen have opened a pilot plant in Eslöv for fermentation. The plant will be used for manufacturing products for clinical studies, process development, and the launch of new products. The facility will enable BioGaia to have control over the entire development process, from early phase to in-house pilot scale manufacturing. The pilot plant will help BioGaia continue to be at the forefront of new product formulations.
BioGaia is developing probiotic products and expanding its product portfolio with new bacterial strains, developed together with the wholly-owned subsidiary MetaboGen. To take new strains through clinical development and towards eventual launch, the two companies are now opening a pilot plant in Eslöv for fermentation.
The development of next-generation probiotic products often requires special conditions and new technical solutions. To meet these requirements, BioGaia and the subsidiary MetaboGen have built a pilot plant in Eslöv. The facility handles manufacturing of bacteria with different requirements during fermentation, both traditional lactobacilli as well as new, extremely oxygen-sensitive strains.
The automated and specialized pilot plant will be used for the controlled manufacturing of products for clinical studies, process development, and manufacturing to launch new products. Together with the capacity of BioGaia Production, the plant gives BioGaia control over the entire development process, from early phase to in-house pilot scale manufacturing.
"For a company whose core is clinically-tested probiotics of the highest standard, the expectation is that this new technology helps BioGaia continue to be at the forefront of new product formulations," says BioGaia's President and CEO, Isabelle Ducellier.
"The pilot facility gives us fantastic opportunities to develop and manufacture our new products under the special conditions that the strains require. I am really looking forward to this new phase where we will take a big step towards the commercialization of new products", says MetaboGen's CEO, Sara Malcus.
MetaboGen is a wholly owned subsidiary that conducts research and product development focusing on the microbiome and its potential for next generation probiotic products. Read more at www.metabogen.se.
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com